ERBB2 as a Prognostic Biomarker in Prostate Cancer: Integration of Single-Cell Transcriptomics, Deep Learning, and Immunohistochemical Validation

Comprehensive Summary

Wang et al presents a study investigating the role of the gene ERBB2 as a prognostic biomarker in prostate cancer by integrating single-cell RNA sequencing, deep learning, and immunohistochemical validation. Researchers identified genes linked to CD8⁺ T-cell exhaustion and metastatic prostate cancer, then used these to build a predictive model for biochemical recurrence (BCR). They found that ERBB2 was a key gene associated with tumor progression and recurrence risk, and the deep learning model showed strong ability to predict patient outcomes. These findings highlight ERBB2 as a potential marker linking immune dysfunction and prostate cancer progression.

Outcomes and Implications

This research is important because predicting biochemical recurrence in prostate cancer is critical for guiding treatment and long-term monitoring. The identification of ERBB2 as a prognostic biomarker suggests it could help clinicians better stratify patients by recurrence risk and potentially target underlying immune-related mechanisms. Clinically, this could improve personalized treatment decisions and follow-up strategies, but further validation in larger patient populations is needed before it can be routinely applied in practice.